A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer

David L. Tait, Patrice S. Obermiller, Sheryl Redlin-Frazier, Roy A. Jensen, Piri Welcsh, Jamie Dann, Mary Claire King, David H. Johnson, Jeffrey T. Holt

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Gene transfer of BRCA1sv (a normal splice variant of BRCA1) into ovarian cancer cells produces growth inhibition in vitro and tumor suppression in nude mouse xenografts. As an initial step toward gene replacement therapy for ovarian cancer, we conducted a Phase I trial to assess the pharmacokinetics and toxicity of i.p. BRCA1sv retroviral vector therapy. Following placement of an indwelling Port-a-Cath in patients, a dose escalation study was performed of four daily i.p. infusions spanning doses from 3 to 300 ml (i.e., 1010 vital particles) at half-log intervals (23 cycles in 12 patients). Gene transfer and expression were documented by PCR, Southern blot, reverse transcription-PCR, and nuclease protection assays. Pharmacokinetics were assessed by PCR and Southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of 12 patients developed an acute sterile peritonitis, which spontaneously resolved within 48 h. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to 4 months. Eight patients showed stable disease for 4-16 weeks, and three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). The vector-related complication of peritonitis was observed in three patients but resolved quickly as in preclinical mouse studies. Ovarian cancer may provide an important model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by i.p. therapy.

Original languageEnglish (US)
Pages (from-to)1959-1968
Number of pages10
JournalClinical Cancer Research
Volume3
Issue number11
StatePublished - Nov 1997

Fingerprint

Genetic Therapy
Ovarian Neoplasms
Southern Blotting
Peritonitis
Polymerase Chain Reaction
Neoplasms
Nuclease Protection Assays
Pharmacokinetics
Reoperation
Heterografts
Nude Mice
Reverse Transcription
Antibody Formation
Gene Expression
Antibodies
DNA
Therapeutics
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tait, D. L., Obermiller, P. S., Redlin-Frazier, S., Jensen, R. A., Welcsh, P., Dann, J., ... Holt, J. T. (1997). A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clinical Cancer Research, 3(11), 1959-1968.

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. / Tait, David L.; Obermiller, Patrice S.; Redlin-Frazier, Sheryl; Jensen, Roy A.; Welcsh, Piri; Dann, Jamie; King, Mary Claire; Johnson, David H.; Holt, Jeffrey T.

In: Clinical Cancer Research, Vol. 3, No. 11, 11.1997, p. 1959-1968.

Research output: Contribution to journalArticle

Tait, DL, Obermiller, PS, Redlin-Frazier, S, Jensen, RA, Welcsh, P, Dann, J, King, MC, Johnson, DH & Holt, JT 1997, 'A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer', Clinical Cancer Research, vol. 3, no. 11, pp. 1959-1968.
Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clinical Cancer Research. 1997 Nov;3(11):1959-1968.
Tait, David L. ; Obermiller, Patrice S. ; Redlin-Frazier, Sheryl ; Jensen, Roy A. ; Welcsh, Piri ; Dann, Jamie ; King, Mary Claire ; Johnson, David H. ; Holt, Jeffrey T. / A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 11. pp. 1959-1968.
@article{186af4be9c884b138c4793bbdae19789,
title = "A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer",
abstract = "Gene transfer of BRCA1sv (a normal splice variant of BRCA1) into ovarian cancer cells produces growth inhibition in vitro and tumor suppression in nude mouse xenografts. As an initial step toward gene replacement therapy for ovarian cancer, we conducted a Phase I trial to assess the pharmacokinetics and toxicity of i.p. BRCA1sv retroviral vector therapy. Following placement of an indwelling Port-a-Cath in patients, a dose escalation study was performed of four daily i.p. infusions spanning doses from 3 to 300 ml (i.e., 1010 vital particles) at half-log intervals (23 cycles in 12 patients). Gene transfer and expression were documented by PCR, Southern blot, reverse transcription-PCR, and nuclease protection assays. Pharmacokinetics were assessed by PCR and Southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of 12 patients developed an acute sterile peritonitis, which spontaneously resolved within 48 h. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to 4 months. Eight patients showed stable disease for 4-16 weeks, and three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). The vector-related complication of peritonitis was observed in three patients but resolved quickly as in preclinical mouse studies. Ovarian cancer may provide an important model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by i.p. therapy.",
author = "Tait, {David L.} and Obermiller, {Patrice S.} and Sheryl Redlin-Frazier and Jensen, {Roy A.} and Piri Welcsh and Jamie Dann and King, {Mary Claire} and Johnson, {David H.} and Holt, {Jeffrey T.}",
year = "1997",
month = "11",
language = "English (US)",
volume = "3",
pages = "1959--1968",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer

AU - Tait, David L.

AU - Obermiller, Patrice S.

AU - Redlin-Frazier, Sheryl

AU - Jensen, Roy A.

AU - Welcsh, Piri

AU - Dann, Jamie

AU - King, Mary Claire

AU - Johnson, David H.

AU - Holt, Jeffrey T.

PY - 1997/11

Y1 - 1997/11

N2 - Gene transfer of BRCA1sv (a normal splice variant of BRCA1) into ovarian cancer cells produces growth inhibition in vitro and tumor suppression in nude mouse xenografts. As an initial step toward gene replacement therapy for ovarian cancer, we conducted a Phase I trial to assess the pharmacokinetics and toxicity of i.p. BRCA1sv retroviral vector therapy. Following placement of an indwelling Port-a-Cath in patients, a dose escalation study was performed of four daily i.p. infusions spanning doses from 3 to 300 ml (i.e., 1010 vital particles) at half-log intervals (23 cycles in 12 patients). Gene transfer and expression were documented by PCR, Southern blot, reverse transcription-PCR, and nuclease protection assays. Pharmacokinetics were assessed by PCR and Southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of 12 patients developed an acute sterile peritonitis, which spontaneously resolved within 48 h. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to 4 months. Eight patients showed stable disease for 4-16 weeks, and three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). The vector-related complication of peritonitis was observed in three patients but resolved quickly as in preclinical mouse studies. Ovarian cancer may provide an important model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by i.p. therapy.

AB - Gene transfer of BRCA1sv (a normal splice variant of BRCA1) into ovarian cancer cells produces growth inhibition in vitro and tumor suppression in nude mouse xenografts. As an initial step toward gene replacement therapy for ovarian cancer, we conducted a Phase I trial to assess the pharmacokinetics and toxicity of i.p. BRCA1sv retroviral vector therapy. Following placement of an indwelling Port-a-Cath in patients, a dose escalation study was performed of four daily i.p. infusions spanning doses from 3 to 300 ml (i.e., 1010 vital particles) at half-log intervals (23 cycles in 12 patients). Gene transfer and expression were documented by PCR, Southern blot, reverse transcription-PCR, and nuclease protection assays. Pharmacokinetics were assessed by PCR and Southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of 12 patients developed an acute sterile peritonitis, which spontaneously resolved within 48 h. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to 4 months. Eight patients showed stable disease for 4-16 weeks, and three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). The vector-related complication of peritonitis was observed in three patients but resolved quickly as in preclinical mouse studies. Ovarian cancer may provide an important model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by i.p. therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030656171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030656171&partnerID=8YFLogxK

M3 - Article

C2 - 9815585

AN - SCOPUS:0030656171

VL - 3

SP - 1959

EP - 1968

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -